Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | QDPR | P09417 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18212194 | 0.84 | LMNA (0.40) | EPHX2LMNASMN1; SMN2HPGD | |
| SCHEMBL16886302 | 0.84 | LMNA (0.40) | EPHX2LMNASMN1; SMN2HPGD | |
| SCHEMBL12586781 | 0.84 | EPHX2 (0.42) | EPHX2EPHX1LMNACYP1A2TDP1 | |
| SCHEMBL26138761 | 0.83 | LMNA (0.42) | LMNASMN1; SMN2HPGDRIPK1 | |
| SCHEMBL3503877 | 0.83 | LMNA (0.46) | LMNASMN1; SMN2HPGD | |
| SCHEMBL27022611 | 0.82 | HPGD (0.52) | LMNASMN1; SMN2HPGD | |
| SCHEMBL16886304 | 0.82 | GAA (0.41) | LMNATDP1SMN1; SMN2HPGD | |
| SCHEMBL16886298 | 0.79 | EPHX2 (0.46) | EPHX2EPHX1LMNARIPK1 | |
| SCHEMBL26501773 | 0.79 | ALDH1A1 (0.39) | LMNASMN1; SMN2HPGD | |
| SCHEMBL13542926 | 0.78 | CHRNB2 (0.45) | EPHX2EPHX1CYP1A2TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-10711020-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190241588-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-08 | — | — | US | disclosed |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-9815859-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815859-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| US-9096518-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL, LTD. (BM) | 2010-11-11 | — | — | US | disclosed |
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | EPHX2 4333/4885EPHX1 4458/4885LMNA 4285/4885 |
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | AR, SHBG, NR5A1 | EPHX2 3675/4885EPHX1 4261/4885LMNA 3917/4885 |
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | EPHX2 1205/4885EPHX1 1351/4885LMNA 3931/4885 |
| US-10711020-B2 | Tricyclic sulfones as RORγ modulators | RORC, RORB, RORA | EPHX2 1602/4885EPHX1 1701/4885LMNA 4148/4885 |
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | EPHX2 1820/4885EPHX1 1615/4885LMNA 1592/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | EPHX2 4333/4885EPHX1 4458/4885LMNA 4285/4885 |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | EPHX2 1957/4885EPHX1 2389/4885LMNA 1009/4885 |
| US-20190241588-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | EPHX2 1205/4885EPHX1 1351/4885LMNA 3931/4885 |
| US-20230133119-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | AR, SHBG, NR5A1 | EPHX2 3719/4885EPHX1 4290/4885LMNA 3918/4885 |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | RORC, RORB, RORA | EPHX2 1602/4885EPHX1 1701/4885LMNA 4148/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | EPHX2 2311/4885EPHX1 1774/4885LMNA 3963/4885 |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | EPHX2 1820/4885EPHX1 1615/4885LMNA 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.